A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Completed
AVEO Pharmaceuticals, Inc.
Phase 2
2007-10-01
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in
treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a
VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking
blood flow to the tumor.
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Completed
AVEO Pharmaceuticals, Inc.
Phase 1
2007-11-01
The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and
Torisel™ given in combination for renal cell cancer. The study will also assess the effects
of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a
VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking
blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the
treatment of advanced renal cell carcinoma.
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
Completed
AVEO Pharmaceuticals, Inc.
Phase 1
2008-06-01
The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with
colorectal cancer and other gastrointestinal cancers. Tivozanib (AV-951) is a targeted
anti-angiogenesis agent that has demonstrated acceptable tolerability in a phase I clinical
trial. This study is designed to test the hypothesis that tivozanib (AV-951) can be combined
with standard FOLFOX6 chemotherapy for the treatment of patients with colorectal and other
gastrointestinal cancers. The purpose of this study is to determine the maximum dose of
tivozanib (AV-951) that can be safely combined with FOLFOX6 chemotherapy, and to evaluate the
safety profile, tolerability, and pharmacokinetics of this combination.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
